BioSpace News Archive

Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative evidence-based solutions for the treatment of chronic pain, today reported financial results for the three months ended March 31, 2018.

--Adjusted EPS Higher Than Expected; Outlook for Fiscal 2018 Net Sales and Adjusted Profitability Affirmed--

Medical and Value Hearing Health Performance Drive Double-Digit First Quarter Sales Gains and Profitability

Brookdale Senior Living Inc. (NYSE: BKD) (“Brookdale” or the “Company”) announced results for the quarter ended March 31, 2018.

Progress Update on INSPIRE 2.0 Trial, Finance Officer Appointment

IND filed for UCART22 clinical investigation in ALL patients Allogene takes over Pfizer’s rights under the Research and License Agreement with Cellectis, to accelerate development and commercialization of allogeneic off-the-shelf UCART therapies Harvard’s Wyss Institute partners with Cellectis to recode the human genome using TALEN® gene editing technology

The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved DARZALEX® (daratumumab) in combination with VELCADE® (bortezomib).

Evolus, Inc. announced that its board of directors has named David Moatazedi as President and Chief Executive Officer.